Tesofensina
Anti-obesity candidate with real phase 2 RCTs; not to be confused with a “peptide supplement”.
Updated:
Affiliate link to this product’s page on Peptira. We may earn a commission at no extra cost to you. Code KAREL. Disclosure
Quick summary
Tesofensine is not a peptide: it is a monoamine reuptake inhibitor investigated for weight loss. The 2008 Lancet trial (TIPO-1) showed dose-dependent weight loss vs placebo at 24 weeks, with mild stimulant/anticholinergic-type adverse effects (dry mouth, nausea, insomnia). Tableted research products are not an authorized medication.
Studied for
How it works
↑ synaptic serotonin, norepinephrine, and dopamine → less appetite / more satiety (classic pharmacology of central anorexigenics).
What the research says
PubMed 18950853 — obesity RCT. ClinicalTrials NCT00394667. Subsequent reviews of the candidate. Regulatory status: not approved as a standard obesity therapy (unlike semaglutide/tirzepatide).
Evidence level
B–C — positive phase 2; without approval / consolidated commercial phase 3
What's most reported
- Phase 2 weight loss (~4–10% depending on dose in the Lancet trial, vs ~2% placebo+diet)
- Dry mouth, nausea, constipation, insomnia
Common side effects
From the trial: GI, insomnia, dry mouth; monitoring of HR/BP typical for the class. Interactions with other serotonergics/stimulants are possible. Research product: non-pharmaceutical grade quality not guaranteed.
Combines / does not combine
Do not combine with SSRIs/MAOIs/other stimulant anorexigenics. Do not stack with research GLP-1s without supervision — risk of unstudied additive effects with that product.
Frequently asked questions
It did not complete the regulatory path to broad approval; GLP-1s changed the standard.
No.
Keep exploring
Keep learning
Related peptides
Educational content. Not medical advice or usage guidance. Research products are not approved medications unless otherwise indicated.